Tom Powles shares final analysis results of BOND-003 trial for High-Risk NMIBC

Tom Powles, Professor at the University of London, shared a post on X:

“BOND-003: The final analysis of Intravesical Cretostimogene Grenadenorepvec (n=112). for High-Risk BCG unresponsive NMIBC with CIS. CR=75% & 12 months DFS= 50% (of ITT population). This looks in line with other adenoviral gene therapies – INFa (adstiladein).”